Video

Q&A With Jim Januzzi From Massachusetts General Hospital: Using Biomarkers To Learn More About Heart Failure

Author(s):

Treating heart failure can be a delicate practice for doctors depending on the severity of the condition. Finding new ways to help these patients is moving from the clinical side of medicine into the laboratory to find more exacting treatment methods.

Treating heart failure can be a delicate practice for doctors depending on the severity of the condition. Finding new ways to help these patients is moving from the clinical side of medicine into the laboratory to find more exacting treatment methods.

James (Jim) Januzzi, MD, from Massachusetts General Hospital discussed work being done in this field during the American Heart Association's Annual Scientific Sessions in Orlando.

Patients with chronic heart failure may not always be at risk of a fatal cardiac event but there has not been a clear diagnosis of what worsening heart failure means. Researchers are looking to find more definitive answers for these and other questions.

Related Videos
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
Orly Vardeny, PharmD | Credit: JACC Journals
Christian T. Ruff, MD, MPH: Abelacimab Cuts Bleeding Risk Versus Rivaroxaban| Image Credit: Brigham & Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.